Comparing the current results to its competitors, Sellas Life Sciences Group Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.29 %, recorded in the same quarter.
Sellas Life Sciences Group Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical, specialty pharmaceutical, and biotechnology firms with substantially greater resources. In the oncology therapeutic market, competitors range from large to mid-sized companies with approved products and those engaged in clinical development. Key competitors in acute myeloid leukemia (AML) include AbbVie/Genentech (Venclexta), Pfizer (Mylotarg), Daiichi-Sankyo (Vanflyta), Rigel Pharmaceuticals (Rezlidhia), Syndax Pharmaceuticals (Revumenib), and Bristol Myers Squibb (Vidaza and Onureg). Additional competitors developing therapies for relapsed or refractory AML include Curis (emavusertib) and Delta-Fly Pharma. For selective CDK9-targeting therapies such as SLS009, competitors include Sumitomo Dainippon Pharma (TP-1287), Cothera Bioscience (zotiraciclib), and Prelude Therapeutics (PRT2527). These competitors often possess greater resources and expertise in research and development, manufacturing, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Competition also exists in recruiting qualified personnel and conducting clinical trials, with smaller or early-stage companies potentially playing significant roles through collaborations with larger firms.
May 1, 2024
SELLAS Life Sciences Group recently unveiled encouraging preliminary results from their Phase 2 study of SLS009 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) who carry the ASXL1 mutation. The study has demonstrated a remarkable 100% response rate in patients treated at the optimal dose level. Additionally, SELLAS has filed for intellectual property (IP) protection specifically related to the ASXL1 mutation, recognizing its high prevalence in myeloid malignancies and solid tumors, and the significant market potential it holds. These findings provide hope for a new treatment option with broader applications for patients battling AML and related malignancies.The Study s PromiseAML is a c...
March 26, 2024
SELLAS Announces Promising Data from Phase 2a Study of SLS009 in Relapsed/Refractory AML and Receives FDA Fast Track DesignationSELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a leading clinical biopharmaceutical company focused on developing innovative cancer therapies, has recently made significant advancements in the study and development of SLS009 for the treatment of relapsed/refractory acute myeloid leukemia (AML). The company has announced positive topline data from the Phase 2a study of SLS009 and received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for this potential breakthrough therapy.The Phase 2a study of SLS009 involved evaluating its safety and efficacy in patients ...
January 9, 2024
Acute myeloid leukemia (AML) is a challenging and aggressive form of blood cancer that requires effective treatment options. SELLAS Life Sciences recently received Fast Track Designation from the FDA for SLS009, a potential therapy for relapsed/refractory AML. This article aims to provide an extensive review of the recent developments and updated data from the Phase 2a study of SLS009, highlighting its safety, efficacy, and potential impact on the treatment landscape for AML.Overview of SLS009:SLS009 is a novel investigational agent developed by SELLAS Life Sciences, specifically designed to target AML. It is a targeted agent that focuses on the WT1 protein, a tumor marker expressed in various hematologic ma...
January 3, 2024
SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, is known for its pioneering focus on the development of novel cancer immunotherapies. It is a significant contributor to the field of medicine, working relentlessly to develop innovative therapies that could potentially alter the landscape of cancer treatment. As the company steps into the new year, it unveils its corporate updates and outlines key milestones slated for 2024.In the quest to keep stakeholders informed, SELLAS will be hosting an interactive Corporate Update Webinar today, on January 3, 2024, at 8:30 am Eastern Time. The event is intended to apprise business partners, investors, healthcare practitioners, and the genera...
December 21, 2023
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell LymphomasSellas Life Sciences Group, Inc. (Sellas), a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for a variety of cancer indications, has announced that their drug candidate, SLS009, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of peripheral T-cell lymphomas (PTCL). This designation represents a significant milestone in Sellas efforts to bring effective treatments to patients with this rare and often aggressive form of cancer.Peripheral T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders der...
December 4, 2023
SELLAS Life Sciences, a biopharmaceutical company focused on developing novel cancer immunotherapies, has recently received a positive recommendation from the REGAL Independent Data Monitoring Committee (IDMC) for their investigational drug, Galinpepimut-S, in the treatment of Acute Myeloid Leukemia (AML). The IDMC recommended the continuation of the Phase 3 REGAL trial without any modifications, marking a significant milestone in the development of this potential treatment option for AML patients. AML is a type of blood cancer characterized by the rapid growth of abnormal cells in the bone marrow, which interfere with the production of healthy blood cells. This aggressive form of leukemia comprises a si...
November 29, 2023
SELLAS Life Sciences, a leading global biopharmaceutical company, recently announced that it has successfully reached its target enrollment for the Phase 3 REGAL trial of Galinpepimut-S in patients with Acute Myeloid Leukemia (AML), excluding China. This encouraging development marks a significant milestone in the company s efforts to bring a potential breakthrough therapy to AML patients who are in desperate need of new treatment options. AML, a type of blood cancer characterized by the excessive production of abnormal white blood cells, is a complex and challenging disease to treat. Current treatment options, such as chemotherapy and stem cell transplantation, have limitations and often result in poor ...
Publicly Traded Peers of Sellas Life Sciences Group Inc
Zymeworks Inc Share Performance
+5.50%
30 Days
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Sources:
Sellas Life Sciences Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sellas Life Sciences Group Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
